Compare OPK & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPK | MLTX |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2011 | 2020 |
| Metric | OPK | MLTX |
|---|---|---|
| Price | $1.59 | $11.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 16 |
| Target Price | $4.15 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 2.9M | 1.5M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $606,879,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $9.46 |
| 52 Week High | $1.86 | $23.29 |
| Indicator | OPK | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 44.69 |
| Support Level | $1.46 | $10.67 |
| Resistance Level | $1.58 | $13.64 |
| Average True Range (ATR) | 0.09 | 0.83 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 9.52 | 14.06 |
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.